Morgan Stanley’s Enveric Biosciences ENVB Stock Holding History

Morgan Stanley’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.8K	Buy	+10,733	New	+$25.8K	﹤0.01%	6922
2025 Q3	–	Sell	-1,085	Closed	-$15.8K	–	8220
2025 Q2	$15.8K	Buy	+1,085	New	+$16.4K	﹤0.01%	6720
2024 Q2	–	Hold	0	–	-$1	–	7876
2024 Q1	–	Hold	0	–	–	–	7811
2023 Q4	–	Hold	0	–	–	–	7805
2023 Q3	–	Hold	0	–	–	–	7594
2023 Q2	–	Hold	0	–	–	–	7630
2023 Q1	–	Hold	0	–	–	–	7695
2022 Q4	–	Hold	0	–	–	–	7855
2022 Q3	–	Hold	0	–	–	–	7742
2022 Q2	–	Hold	0	–	–	–	7847
2022 Q1	–	Hold	0	–	–	–	7999
2021 Q4	–	Hold	0	–	–	–	8004
2021 Q3	–	Hold	0	–	–	–	7953
2021 Q2	–	Hold	0	–	–	–	7757
2021 Q1	–	Hold	0	–	–	–	7501
2020 Q4	–	Hold	0	–	–	–	7053
2020 Q3	–	Hold	0	–	–	–	6756
2020 Q2	–	Hold	0	–	–	–	6633
2020 Q1	–	Hold	0	–	–	–	6602
2019 Q4	–	Hold	0	–	–	–	6678
2019 Q3	–	Hold	0	–	–	–	6668
2019 Q2	–	Hold	0	–	–	–	6672
2019 Q1	–	Hold	0	–	–	–	6617
2018 Q4	–	Hold	0	–	–	–	6625
2018 Q3	–	Hold	0	–	–	–	6730
2018 Q2	–	Hold	0	–	–	–	6686
2018 Q1	–	Hold	0	–	–	–	6421
2017 Q4	–	Hold	0	–	–	–	6587

Other funds holding ENVB

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's ENVB Position: Q2 2026 in Review

Morgan Stanley opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 10,733 shares worth $14.8K. The stake represents ﹤0.01% of the portfolio and ranks #6922 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in ENVB as recently as Q2 2025.

Morgan Stanley first reported a position in ENVB in Q2 2025 and has held it in 2 quarters since. The position peaked at $15.8K in Q2 2025. 25 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

Morgan Stanley held 10,733 shares of Enveric Biosciences worth $14.8K as of Q2 2026.
Enveric Biosciences was a new Morgan Stanley position in Q2 2026.
Enveric Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6922 holding.
Morgan Stanley first reported a position in Enveric Biosciences in Q2 2025 and has held it in 2 quarters since.
Morgan Stanley's Enveric Biosciences position peaked at $15.8K in Q2 2025.
25 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.